The abstract is read at the publisher; the summary is JClub's.
In early symptomatic Alzheimer disease with low-to-medium tau pathology, ceperognastat at 0.75 mg or 3 mg did not slow iADRS progression at 100 weeks versus placebo.
- Why it matters: OGA inhibition is hypothesized to reduce aggregated, hyperphosphorylated tau and neurofibrillary tangle formation, but its clinical efficacy in early symptomatic AD is unknown.
- What they did: In a double-blind, randomized, placebo-controlled phase 2 trial at 72 sites in 5 countries, participants received once-daily oral ceperognastat (0.75 mg, n = 110; 3 mg, n = 108) or placebo (n = 108), with primary iADRS change modeled in a tau-PET–defined subgroup.
- The result: At 100 weeks, posterior mean iADRS change was -8.39 (0.75 mg), -13.27 (3 mg), and -10.07 (placebo), with progression ratios of 0.84 (95% CrI, 0.66-1.04) and 1.32 (CrI, 1.10-1.58); no clinically meaningful benefit on secondary clinical outcomes and more serious/severe treatment-emergent adverse events with 3 mg.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.